JOHN ECKARD: Open Payments
NPI 1083603187 · BEDFORD, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$844 in 44 payments from 11 companies in 2025. Trend: 2023 $565 · 2024 $833 · 2025 $844
Food & beverage: $844
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $173 |
| Vanda Pharmaceuticals Inc. | 6 | $162 |
| E.R. Squibb & Sons, L.L.C. | 6 | $113 |
| Teva Pharmaceuticals USA, Inc. | 4 | $101 |
| Otsuka America Pharmaceutical, Inc. | 5 | $87 |
| Alkermes, Inc. | 5 | $79 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| Lundbeck LLC | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
Products named: VRAYLAR, FANAPT, REXULTI, COBENFY, ARISTADA, AUSTEDO XR, CAPLYTA, UZEDY.
Industry payments across IN — which companies pay providers there.
